Benefits of Leveraging Real World Data (RWD) to Conduct Long-Term Follow Up
Meet the speakers
Andrew Mackinnon
VP & GM eConsent, Medable
Devin Gilliam
Business Development, Clinical Trials, Datavant
Karma Rabon Stith
Global Oncology RWE COE Lead, Pfizer
Robert Zambon
VP, Transformational Design, Syneos Health
About the webinar
Conducting long term follow up studies to ensure that life-saving therapies can be brought to patients safely is challenging. This places a burden on patients participating in the studies and operational challenges on life sciences study sponsors.
Connecting sources of real world data (RWD) to clinical trials data can create a more seamless process for conducting long-term follow up studies.
In this webinar, panelists will discuss how this approach enables many benefits, including the ability to:
- Supplement data for patients lost to follow up
- Augment trial data to help explain non-responders and adverse events
This approach can be particularly beneficial in specific therapeutic areas, including:
- Cell and gene therapies: high regulatory burden (up to 15 years of data collection)
- Oncology: endpoints such as overall survival can be assessed for Accelerated Approval
- COVID-19: exploration of delayed adverse events
